Eris Lifesciences Q3 Results: Revenue Growth, Profit Strength

Ahmedabad-based Eris Lifesciences Ltd, a leading player in branded formulations, announced its Q3 FY26 results, reflecting resilience in India’s pharmaceutical sector. Consolidated revenue from operations stood at ₹8.07 billion, while net profit reached ₹997.2 million, underscoring the company’s ability to sustain profitability amid competitive market conditions.

The company’s performance was supported by strong demand in chronic therapies such as cardiology, diabetes, and dermatology, alongside expansion in specialty healthcare. Operational efficiency and cost optimization further contributed to improved margins.

Key Highlights

• Revenue Performance: Consolidated revenue from operations at ₹8.07 billion.
• Profit Growth: Net profit stood at ₹997.2 million, reflecting healthy margins.
• Therapy Strength: Strong demand in chronic therapies drove growth.
• Operational Efficiency: Cost optimization supported profitability.
• Market Positioning: Continued expansion in specialty healthcare segments.

Eris Lifesciences’ Q3 results reaffirm its position as a key player in India’s pharmaceutical industry, with a focus on chronic therapies and sustainable growth strategies.

Sources: BSE Filings, Economic Times, Business Standard